AxS007 / Nanocarry Therapeutics - LARVOL DELTA

Preclinical efficacy and brain uptake of an insulin-mediated nanoparticle co-delivering trastuzumab and pertuzumab (AxS007) in HER2+ breast cancer brain metastasis models. (ASCO 2026) - "AxS007 showed enhanced BBB penetration and increased brain antibody exposure, with improved preclinical efficacy versus free antibodies in HER2+ breast cancer brain metastasis models. These findings support further translational advancement of AxS007 toward first-in-human clinical testing."

First-in-human • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Nanocarry Therapeutics’ Brain Penetrating Nanoplatform Selected by the NCI Nanotechnology Characterization Laboratory for its Preclinical Characterization Program (GlobeNewswire) - "Nanocarry Therapeutics...announced the selection of its lead product, AxS007, by the U.S. National Cancer Institute’s (NCI’s) Nanotechnology Characterization Laboratory (NCL) for comprehensive preclinical characterization....Through this collaboration, the NCL will conduct detailed preclinical evaluations of AxS007. These studies will support the advancement of AxS007 towards filing an Investigational New Drug (IND) application with the FDA and facilitate future clinical development."

Preclinical • Breast Cancer • Oncology • Solid Tumor